Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Farther Finance Advisors LLC

Farther Finance Advisors LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,293 shares of the biopharmaceutical company’s stock after acquiring an additional 1,518 shares during the quarter. Farther Finance Advisors LLC’s holdings in Gilead Sciences were worth $1,782,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. HHM Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the period. YANKCOM Partnership acquired a new position in Gilead Sciences in the 4th quarter valued at $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences during the 4th quarter worth $29,000. Crews Bank & Trust purchased a new stake in shares of Gilead Sciences during the 4th quarter worth $31,000. Finally, Stephens Consulting LLC boosted its position in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 260 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. UBS Group boosted their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Wolfe Research assumed coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 target price on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Finally, Royal Bank of Canada boosted their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $104.52.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 311,285 shares of company stock valued at $31,284,910 in the last 90 days. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Trading Down 0.6 %

NASDAQ GILD opened at $113.35 on Friday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a 50-day moving average of $101.42 and a 200-day moving average of $92.47. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a market cap of $141.16 billion, a P/E ratio of 306.35, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.79%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.